Sanofi (SAN) Earnings Call Transcripts

Sanofi's Latest Earnings Call - Q1 FY2026

Sanofi reported strong Q1 2026 results with net sales growing 13.6% to EUR 10.5 billion and business EPS increasing by 14%. This performance was driven by robust sales from Dupixent, recent product launches, and acquisitions. Management confirmed guidance for high single-digit sales growth and EPS growth slightly faster than sales for the full year, despite anticipating tougher comparisons in H2. The company highlighted significant contributions from new launches like ALTUVIIIO and Beyfortus, and continued strong performance from Dupixent.

Reported metrics

Guidance from management

Sanofi maintained its guidance for high single-digit sales growth at constant exchange rates and business EPS growth slightly faster than sales for 2026. The company anticipates approximately EUR 400 million from divestments.

What management said

Yes. So I would ask Houman also to complement here. So first of all, your question was on the LCM profile of Dupixent. And we are evaluating strategic options, a broad set of strategic options as Olivier reiterated in his remarks, one is on IP. The other part is on formulations. Houman will talk a little bit about the formulations but there are broader options for Dupixent that we're looking at and that we're consid...

Manuela, thank you for that. Very quickly, James, I think just to be super clear, with a high data we're going into asthma, development plan for that will be relatively conventional and we'll give you more details of that alongside our partner Regeneron going forward. Importantly, with a formulation that we anticipate going relatively broadly -- the formulation has been well worked out and will be germane and pertine...

What analysts pressed on

Analysts questioned the impact of pricing pressures on Dupixent in the U.S. and the competitive landscape in immunology. There were also inquiries about the development timelines for new formulations and potential patent extensions.

Main topics on the call

• Product Launch Performance — Sanofi's new product launches, including ALTUVIIIO and Beyfortus, showed strong sales growth, with ALTUVIIIO sales up 42% to EUR 325 million. Management emphasized the success of these launches in driving overall sales m...
• Dupixent Sales Growth — Dupixent sales reached EUR 4.2 billion, driven by market penetration and new indications. Management noted, 'Dupixent remains the #1 prescribed biologic medicine,' and expects continued volume-driven growth.
• Vaccine Segment Performance — Vaccine sales were EUR 1.3 billion, with growth supported by the integration of Heplisav-B following the Dynavax acquisition. Management highlighted the resilience and depth of the vaccine business.
• Rare Disease Segment Growth — Sanofi's rare disease segment grew by 20% to nearly EUR 1.8 billion, driven by Ayvakit and ALTUVIIIO. This reflects the company's focus on innovation and new launches in this area.

Read the full Sanofi transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 121 Sanofi earnings call transcripts on record, spanning January 14, 2020 to July 30, 2026. Based on this history, Sanofi reports quarterly. The most recent call on file is dated July 30, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

SAN

Exchange

ENXTPA

Country

FR

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

121

First call

January 14, 2020

Most recent

July 30, 2026

Reporting cadence

quarterly